Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial

CONTEXT: Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly. There are also limited data for the long-acting lanreotide formulation. OBJECTIVE: The aim of the study was to better characterize the effects o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Caron, Philippe J., Bevan, John S., Petersenn, Stephan, Flanagan, Daniel, Tabarin, Antoine, Prévost, Gaëtan, Maisonobe, Pascal, Clermont, Antoine
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2014
Assuntos:
Endocrine Care
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4009579/
https://ncbi.nlm.nih.gov/pubmed/24423301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2013-3318
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados